

Chapter 12

Cytokines and the early vein graft: Strategies to enhance durability

C. Keith Ozaki, MD, *Gainesville, Fla*

This brief review focuses on experimental studies linking the proinflammatory cytokine tumor necrosis factor- α to accelerated vein graft failure in the broader historical context of vein graft research. From some perspectives, the field appears ripe for transfer of cytokine knowledge and therapeutic approaches that have evolved in other systems to vascular surgery problems. However, the complexity of vein graft disease suggests that more robust research approaches, such as broadening of the scope beyond focus on single mediators and neointimal hyperplasia, will be necessary to reach translatable strategies to prolong human vein graft durability. (*J Vasc Surg* 2007;45:92A-98A.)

Surgical bypass with autologous vein remains an evidence-based treatment of choice for selected patients with infrainguinal lower extremity or coronary occlusive disease. However, contemporary data show that almost 40% of lower extremity vein bypass grafts develop occlusive lesions or fail within a year,¹ and almost half of cardiac bypass patients will lose ($\geq 75\%$ stenosis) a vein graft within a year.² Because many technical avenues for improved patency have been exhausted, the future of enhancing the durability of these reconstructions lies in a better knowledge of and interventions based on the biology of the vein graft wall.

This article briefly reviews vein graft failure research to date and then focuses on the proinflammatory cytokine tumor necrosis factor- α (TNF- α) and the early vein graft. Finally, the current status of the field is outlined in the context of cytokine-based research, and challenges and opportunities for the future are discussed. Certainly, a multitude of biochemicals, including growth factors and cell cycle regulators, have been linked to mechanisms of vein graft failure, and the following is by no means comprehensive.

EVOLUTION OF CURRENT VEIN GRAFT CONCEPTS

Vein grafts undergo a defined sequence of anatomic adaptations after placement, although not all favor long-term patency. The principal cause of failure is traditionally cited as the development of neointimal hyperplasia that leads to an obliterative stenosis.³⁻⁷ Early work in the vein graft research field focused on mechanical factors.^{3-5,8} Like arteries, vein graft wall structure adapts to the hemody-

namic environment,^{9,10} although there may be some subtle wall differences.⁵ Intimal hyperplasia has been noted to occur at vein graft areas of low flow,³ probably areas of low wall shear stress.^{4,8} Conversely, high flow appears to have protective effects^{6,11} in association with decreased wall inflammation.¹² The early 1990s also brought a recognition of the importance of circumferential wall tension on the adapting vein graft.^{5,13}

The 1990s saw increased recognition in vascular biology of the interplay between the inflammatory and cardiovascular systems. The arterial wall response to injury was associated with early inflammatory events, including monocyte and T-cell adhesion to vascular endothelial cells.¹⁴⁻¹⁶ Platelet activation and mural thrombus formation were also implicated in this cascade, as well as cytokine and growth factor elaboration, all leading to subsequent vascular remodeling¹⁷ through cellular migration, proliferation, and matrix deposition.^{14-16,18,19} In the mid-1990s, these paradigms began to transfer to the vein graft arena.²⁰ Works specifically examined the role of inflammatory mediators in vein graft failure.^{10,21-24} For instance, the macrophage was identified as a pivotal cellular mediator of vein graft neointimal hyperplasia, with macrophage depletion suppressing this process.²²

Despite incremental progress over these decades, specific cause-and-effect links between hemodynamic factors, inflammatory biochemical mediators, cellular effectors, and vein wall adaptations remain lacking. Thus, not surprisingly, few therapeutic agents to improve vein graft durability have been identified. Antiplatelet and anticoagulant approaches show only a modest benefit under specific circumstances.^{25,26} Recent trials testing edifoligide (an oligonucleotide decoy that binds to and inhibits E2F transcription factors) failed to yield substantial clinical benefit.^{1,2}

PROINFLAMMATORY CYTOKINES AND VEIN GRAFT FAILURE

Proinflammatory cytokines such as TNF- α and interleukin-1 β (IL-1 β) were implicated in vein graft intimal hyperplasia

From the University of Florida College of Medicine and the Malcom Randall Veterans Affairs Medical Center.

Competition of interest: none.

Reprint requests: C. Keith Ozaki, MD, PO Box 100286, Gainesville, FL 32610-0286 (e-mail: Ozaki@surgery.ufl.edu).

0741-5214/\$32.00

Copyright © 2007 by The Society for Vascular Surgery.

doi:10.1016/j.jvs.2007.02.032

almost a decade ago,^{10,23} although the initiating factors for their expression and the biologic implications of these inflammatory mediators in vein wall adaptations remained largely unknown. Expanding knowledge in cytokine-driven inflammatory pathways in other organ systems has led to effective methods for treating pathologies such as rheumatoid arthritis and inflammatory bowel disease,²⁷⁻³⁵ and several anti-inflammatory cytokine-based pharmacologic compounds have emerged.³⁶⁻³⁸ Although anti-inflammatory cytokine therapies have received recent attention as a means to abrogate primary arterial occlusive disease,³⁹ cytokine manipulation strategies remain relatively unexplored with regards to vein graft failure.

TNF- α is a pleiotropic proinflammatory cytokine.^{40,41} Its expression is controlled at the level of both gene transcription and translation, and it can be synthesized by several cell lines relevant to vascular biology, including macrophages, T cells, endothelial cells, fibroblasts, and smooth muscle cells.^{42,43} This potent proinflammatory cytokine is initially synthesized and processed to a transmembrane form.⁴⁴ TNF- α -converting enzyme (TACE), a member of the matrix metalloproteinase superfamily, releases TNF- α from the cell surface,^{45,46} and as a homotrimer, the soluble TNF- α elicits responses in distal target cells.⁴³ Since its description over three decades ago, several related ligands have been described and are grouped in a TNF superfamily of genes.⁴⁷

The tissue response to TNF- α is mediated through two distinct receptors, p55 (type 1 TNF receptor) and p75 (type 2 TNF receptor).^{40,48} These receptors belong to a large TNF receptor superfamily that also includes nerve growth factor receptor, CD95, and Apo2.^{47,49,50} Most cell types coexpress both TNF receptors, although expression of the two receptors appears to be differentially regulated and shows tissue-specific prevalence. Of more importance is that the two receptors differ markedly in their intracellular structure and signaling pathways.^{40,43} Most of the proinflammatory responses classically attributed to TNF- α appear to be mediated by p55 signaling. Studies have shown that administration of TNF- α muteins with specificity for the p55 receptor are proinflammatory and shock inducing, whereas p75 muteins lack any proinflammatory properties.^{51,52}

The theory for a pivotal role for TNF- α in vein graft neointima formation and the related pathologic process of atherogenesis is founded on in vitro cell culture studies, pathologic observations, and a limited number of in vivo studies. In cell culture, TNF- α augments expression of intercellular adhesion molecules in human vascular endothelial cells⁵³ and vascular smooth muscle cells,⁵⁴ thus increasing the possibility of interactions between mononuclear cells, endothelial cells, and smooth muscle cells in neointimal lesions and atherosclerotic plaques. In addition, TNF- α induces prostanoid synthesis, corticosteroids, and other cytokines,⁴¹ and stimulates smooth muscle cell migration⁵⁵ and proliferation after vascular injury.⁴² Through receptors, TNF- α signaling activates caspases, leading to apoptosis, mitogen-activated protein kinases and nuclear

factor- κ B,⁴⁰ which are intracellular mediators linked to numerous fundamental vascular processes.

Few studies have extended these in vitro cell culture and pathologic studies into the more complex in vivo vascular setting. Pathologically, TNF- α co-localizes to areas of occlusive lesions in human arteries⁵⁶ and arterialized vein grafts.²³ In a rabbit heterotopic cardiac transplantation model, in vivo blockade of TNF- α by way of TNF soluble receptor suppressed the acute development of neointima formation by selectively reducing the vascular inflammatory reaction and accumulation of fibronectin.⁵⁷ Nonetheless, the mechanisms of transplant atherosclerosis may be quite different from those of vein graft neointimal hyperplasia. Another set of in vivo experiments demonstrated that exogenous TNF- α causes coronary arteriosclerosis-like cellular changes in a porcine model.⁵⁸

RECENT RESEARCH

For the last decade, our group has probed the role of cytokines in vascular biology. We were initially interested in the role of TNF- α in low shear stress-induced arterial intimal hyperplasia. Using murine models and molecular approaches, we documented induction of TNF- α by acute lowering of arterial wall shear stress.⁵⁹ We have also probed the role of cytokine signaling in the arterial wall response to high shear stress. TNF- α was shown to co-localize to areas of active positive remodeling in response to increased wall shear stress.⁶⁰ Working with collaborators, we completed experiments that used a novel murine model of arteriogenesis, a clinically relevant form of outward arterial remodeling in response to increased wall shear stress. The results showed that TNF- α positively modulated arteriogenesis, probably signaling through the p55 receptor.⁶¹ Recent experiments demonstrate that this process is blocked with the administration of TNF- α inhibitors.⁶²

From these findings linking vascular wall adaptations with changes in hemodynamic environment through proinflammatory and anti-inflammatory cytokine signaling, we hypothesized similar mechanisms in the vein graft. The vein graft is essentially an extreme example of acute hemodynamic change, coupled with a local injury response, leading to morphologic adaptations within the vascular wall. We developed and validated a rabbit bilateral jugular vein into carotid artery vein graft model with clinically relevant differential hemodynamic environments.^{6,63-65} In this model, unilateral reduction in carotid artery (and thus vein graft) flow is accomplished by the placement of 8-0 silk suture ligatures to completely occlude the internal carotid and three of the four primary branches of the external carotid artery. Distal branch ligation results in an immediate 90% flow reduction ($P < .001$) in the vein graft on the ligated side and 36% flow augmentation ($P = .01$) in the contralateral vein graft. The vein grafts develop physiologically relevant levels of wall shear and neointimal hyperplasia volume that is inversely proportional to wall shear.

To initiate studies into molecular mediators of these vein graft adaptations, quantitative real-time two-step poly-




Fig 1. Time course of cytokine messenger RNA (mRNA) expression in a rabbit bilateral vein graft model with differential shear. *TNF- α* , Tumor necrosis factor- α ; *IL-1*, interleukin. Data are combined from two prior *J Vasc Surg* reports.^{66,67}

merase chain reaction (RT-PCR) was performed for *TNF- α* , *IL-1 β* , and *IL-10* on the paired high and low wall shear vein grafts in this rabbit model longitudinally. The results revealed several shear and time-dependent cytokine expression signatures (Fig 1).^{66,67} *TNF- α* induction was maximal at day 1 and gradually decreased over time, but was persistently elevated even 4 weeks later ($P < .001$). Low shear (associated with increased neointimal hyperplasia) resulted in significantly higher *TNF- α* messenger RNA (mRNA) expression ($P = .03$). *TNF- α* was induced 198-fold and 110-fold in low and high shear vein grafts, respectively, by the first day after arterialization. This elevation gradually decreased over time but was persistently elevated from baseline even 4 weeks later ($P < .001$). Over the course of the study, low shear resulted in significantly higher *TNF- α* mRNA ($P < .003$) vein graft wall expression.

Although the general expression pattern of *IL-1 β* expression mirrored that of *TNF- α* , several notable differences exist. At day 1, *IL-1 β* was induced a striking 1188-fold and 366-fold in low and high shear vein grafts,

respectively, but the return toward baseline was more rapid. Flow impacted *IL-1 β* expression overall ($P < .001$), although the differential was greatest at the 1-day ($P = .002$) and 3-day ($P < .0001$) time points. Consistent with the theory that proinflammatory cytokine mechanisms drive downstream vein graft adaptations, these early quantitative *TNF- α* and *IL-1 β* mRNA level changes were temporally distinct from the time course of later morphologic and cellular changes in the vein graft wall. High proinflammatory cytokine levels (as in the low-flow setting) correlated positively with greater intimal hyperplasia. Immunohistochemistry analysis shows that *TNF- α* and *IL-1 β* protein localize to the vein intima in the first 3 days after graft placement.

Finally, vein graft arterialization more slowly and modestly induced *IL-10* mRNA expression. Overall, this occurred independent of shear ($P = .152$), although there was a statistically significant higher expression for high shear grafts at the 14-day time point ($P < .001$). *IL-10* is an immunosuppressive and anti-inflammatory cytokine produced by T cells, B cells, natural killer cells, and monocyte/macrophage cell lines.^{12,68} It has been shown to suppress the production of numerous inflammatory cytokines, including *TNF- α* .⁴¹ Conversely, *TNF- α* is a principal inducer of *IL-10* biosynthesis.⁶⁹ This acts in a negative feedback loop to suppress *TNF- α* production and processing.

IL-10 is believed to exert its anti-inflammatory effects on the vascular system through inhibition of leukocyte-endothelial cell interactions and inhibition of proinflammatory cytokine and chemokine production.^{12,68} In support of the hypothesis that the anti-inflammatory cytokine *IL-10* downregulates vein graft neointimal hyperplasia, researchers have demonstrated an effect of *IL-10* on vascular smooth muscle cell proliferation. Physiologic doses of *IL-10* inhibited *TNF- α* and basic fibroblast growth factor-stimulated DNA synthesis and cell proliferation,⁷⁰ suggesting that endogenous *IL-10* not only suppresses proinflammatory cytokine expression, but also may antagonize pathologic vascular remodeling induced by cytokines such as *TNF- α* .⁷⁰

These results^{66,67} in the context of the medical literature^{10,23,71-75} led our group to formulate the general hypothesis outlined in Fig 2. As an initial step to test this hypothesis, we used a pharmacologic approach to abrogate *TNF- α* signaling in the early vein graft of our validated rabbit model.⁶⁶ Animals received pegylated soluble *TNF- α* type I receptor (PEG s*TNF-RI*; Amgen, Thousand Oaks, Calif) or vehicle with either short-term or long-term dosing. PEG s*TNF-RI* is a 20-kd molecule containing a homodimer of human p55 covalently linked to a polyethylene glycerol backbone.⁷⁶ Molecular modification of these pegylated receptors through deletion of 1.4 intracellular domains reduces immunogenicity but has no impact on ligand binding.⁷⁷ Because of a conserved sequence homology, the compound has been demonstrated to abrogate the adaptive immune response across a range of species, including rabbits.^{76,78} After 14 to 28 days, grafts were analyzed. PEG s*TNF-RI* was found in high concentrations in the serum




Fig 2. Hypothetic mechanisms by which proinflammatory and anti-inflammatory cytokines may interplay with wall shear to modulate vein graft wall adaptations. *TNF* α , Tumor necrosis factor- α ; *TACE*, TNF- α -converting enzyme; *IL*, interleukin; *SMC*, smooth muscle cell.

and localized to neointimal hyperplasia microscopically. Both high-flow and low-flow vein grafts from treated animals demonstrated similar volumes of neointimal hyperplasia compared with controls. PEG sTNF-R1 had minimal impact on vascular wall cell turnover, as reflected by terminal deoxynucleotide transferase-mediated deoxy uridine triphosphate nick-end labeling (TUNEL) and anti-Ki-67 assays.⁶⁶

Thus, although placement of a vein into the arterial circulation acutely upregulates TNF- α ^{23,66,75} (whose expression level correlates with the degree of subsequent neointimal hyperplasia), pharmacologic interruption of this signaling pathway has no significant impact on neointimal hyperplasia or smooth muscle cell proliferation and apoptosis.⁶⁶ These data suggest that early vein graft adaptations can proceed by TNF- α independent mechanisms. Recent work by other investigators, however, supports a differing conclusion. In a study that used p55 receptor knockout animals, functional TNF- α inhibition was shown to attenuate vein graft neointimal hyperplasia.⁷¹ Further investigation is required to elucidate these apparently contrasting observations.

Interesting comparisons can be drawn with observed challenges in application of anti-inflammatory approaches in other pathologies. Early anti-TNF- α clinical trials in acute inflammatory processes, such as sepsis, have had disappointing results⁷⁹⁻⁸² and may be attributed to an over-simplistic view of these disease processes and TNF- α -mediated cytotoxicity.⁴¹ A similar situation arose in the

setting of anti-TNF- α trials for heart failure.⁸³ These experiences may have lessons for work with the vein graft. We have recently completed microarray analyses of vein graft wall in both mice and rabbits (both high flow and low flow).⁸⁴ The results reveal a large number of gene perturbations across multiple families of mediators. These results show that the overwhelming determinant of the wall's transcriptome is the temporal relationship with the operative graft placement; that is, the trauma of the operation itself, rather than the details (eg, neointimal volume) of the wall adaptation. Thus, it may be naive to believe that abrogation of a single mediator would have substantial lasting impact on the final morphology of the wall. Perhaps strategies that block central signaling molecules that control numerous genes for various cytokines and adhesion molecules will be effective (eg, nuclear factor- κ B),⁸⁵ although targets such as TNF- α seem to meet this criteria.

FUTURE CONSIDERATIONS AND DIRECTIONS

To date, several lessons have become apparent, and some considerations for future progress are summarized:

- *Single-agent vs multiagent strategies.* Narrowly focused molecular targets hold the appeal of limited unwanted side effects. However, in view of the large number of mediators implicated in the vein graft wall adaptation, perturbation of several pathways may be necessary to consistently achieve substantial and durable effect. For example, multimodality approaches stand as a mainstay of antineoplastic therapies. The multitude of processes involved in vein graft failure support the use of such strategies, yet the rationale and safety of each component must be confirmed, and substantial investigative work will be required to define the composition of this synergistic cocktail.
- *Understanding the interplay of systems (eg, inflammatory, thrombotic), including genetic factors.* Large amounts of information (eg, biologic and genetic) can now be rapidly acquired and analyzed by use of high throughput experimental and statistical techniques. Vascular biologists must embrace contemporary information management and modeling approaches to understand the interplay of these factors in vein graft failure.
- *Broadening focus to the entire conduit wall.* Vein graft researchers must broaden their observations to the behavior of the entire conduit wall, not just the neointima. Adventitial events leading to fibrosis probably contribute substantially to vein graft failure.⁸⁶
- *Consideration of the injured host patient.* Simple harvest dramatically changes the vein wall cellular phenotype.⁸⁷ Furthermore, surgical trauma globally impacts the phenotype of pivotal cells such as the leukocyte,^{88,89} and these effects may all biologically modulate local processes such as vein graft wall adaptations.
- *Delivery strategies—local vs systemic.* Although vein grafts offer the unique situation of ability to treat the

conduit wall,^{1,85,90} more systemic approaches may be needed in view of the extra-wall mediators (eg, circulating cells) that participate in occlusive adaptations.⁹¹

- *Optimization of trial designs to insure gain of new knowledge regardless of outcome.* Animal models of vein graft disease hold substantial biologic relevance limitations, and clinical trials are expensive. Although they certainly broke new ground, as designed, the Project of Ex Vivo Vein Graft Engineering via Transfection (PREVENT) trials^{1,2} failed to generate substantial new biologic insights despite substantial work and fiscal investments. The thoughtful addition of mechanistic end points, when feasible, will ensure some progress independent of human trial outcome.
- *Translation into other arterial occlusive adaptations (eg, primary atherosclerosis, angioplasty restenosis).* Emerging endovascular approaches bring into question the relevance of vein graft research. However, contemporary evidence-based guidelines confirm that a substantial portion of our aging population will require vein conduits for arterial revascularization. In addition, basic biologic mechanisms delineated in the vein graft field hold a strong likelihood of relevance for other vascular responses to injury.

CONCLUSION

Understanding the cytokine-mediated molecular mechanisms of vein graft arterialization may suggest clinical interventions that will alter the conduit's natural history. The field appears especially ripe for transfer of knowledge and therapeutic approaches that have evolved in the arterial system as well as inflammatory mediated processes such as inflammatory bowel disease and arthritis. However, more robust research approaches such as broadening of the scope beyond focus on single mediators and neointimal hyperplasia will be necessary to reach translatable strategies to prolong human vein graft durability.

I gratefully acknowledge the editorial assistance of Dr Scott A. Berceci and Dr Zhilua Jiang.

REFERENCES

- Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. *J Vasc Surg* 2006;43:742-51.
- Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. *JAMA* 2005;294:2446-54.
- Berguer R, Higgins RF, Reddy DJ. Intimal hyperplasia. An experimental study. *Arch Surg* 1980;115:332-5.
- Dobrin PB, Littooy FN, Edean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. *Surgery* 1989;105:393-400.
- Galt SW, Zwolak RM, Wagner RJ, Gilbertson JJ. Differential response of arteries and vein grafts to blood flow reduction. *J Vasc Surg* 1993;17:563-70.
- Jiang Z, Wu L, Miller BL, Goldman DR, Fernandez CM, Abouhamze ZS, et al. A novel vein graft model: adaptation to differential flow environments. *Am J Physiol Heart Circ Physiol* 2004;286:H240-5.
- Meyerson SL, Skelly CL, Curi MA, Shakur UM, Vosicky JE, Glagov S, et al. The effects of extremely low shear stress on cellular proliferation and neointimal thickening in the failing bypass graft. *J Vasc Surg* 2001;34:90-7.
- Morinaga K, Okadome K, Kuroki M, Miyazaki T, Muto Y, Inokuchi K. Effect of wall shear stress on intimal thickening of arterially transplanted autogenous veins in dogs. *J Vasc Surg* 1985;2:430-3.
- Davies MG, Klyachkin ML, Dalen H, Svendsen E, Hagen PO. Regression of intimal hyperplasia with restoration of endothelium-dependent relaxing factor-mediated relaxation in experimental vein grafts. *Surgery* 1993;114:258-70.
- Sterpetti AV, Cucina A, Lepidi S, Randone B, Corvino V, D'Angelo LS, et al. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. *Surgery* 1998;123:461-9.
- Paszkwik JJ, Dardik A. Arterial wall shear stress: observations from the bench to the bedside. *Vasc Endovascular Surg* 2003;37:47-57.
- Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. *Circ Res* 2001;88:877-87.
- Schwartz LB, O'Donohue MK, Purut CM, Mikat EM, Hagen PO, McCann RL. Myointimal thickening in experimental vein grafts is dependent on wall tension. *J Vasc Surg* 1992;15:176-86.
- Schwartz SM, deBlois D, O'Brien ER. The intima. Soil for atherosclerosis and restenosis. *Circ Res* 1995;77:445-65.
- Gimbrone MA J. Atherogenesis: current concepts. *Monogr Pathol* 1995;37:1-11.
- Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 1993;362:801-9.
- Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. *N Engl J Med* 1994;330:1431-8.
- Schwartz SM, Reidy MA, de BD. Factors important in arterial narrowing. *J Hypertens Suppl* 1996;14:S71-81.
- Ross R. Cell biology of atherosclerosis. *Annu Rev Physiol* 1995;57:791-804.
- Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. *Circulation* 1998;97:916-31.
- Hoch JR, Stark VK, Hullett DA, Turnipseed WD. Vein graft intimal hyperplasia: leukocytes and cytokine gene expression. *Surgery* 1994;116:463-70.
- Hoch JR, Stark VK, van Rooijen N, Kim JL, Nutt MP, Warner TF. Macrophage depletion alters vein graft intimal hyperplasia. *Surgery* 1999;126:428-37.
- Faries PL, Marin ML, Veith FJ, Ramirez JA, Suggs WD, Parsons RE, et al. Immunolocalization and temporal distribution of cytokine expression during the development of vein graft intimal hyperplasia in an experimental model. *J Vasc Surg* 1996;24:463-71.
- Ryomoto M, Wolff RA, Tomas JJ, Miyamoto T, Hoch JR. 17beta-estradiol attenuates intimal hyperplasia and macrophage accumulation with a reduction in monocyte chemoattractant protein 1 expression in a vein graft model. *J Vasc Surg* 2002;36:613-21.
- Bequemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine apres Pontage Femoro-Poplite and the Association Universitaire de Recherche en Chirurgie. *N Engl J Med* 1997;337:1726-31.
- Sarac TP, Huber TS, Back MR, Ozaki CK, Carlton LM, Flynn TC, et al. Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure. *J Vasc Surg* 1998;28:446-57.
- Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2003;42(suppl 2):ii22-8.
- Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. *Pediatric Rheumatology Collaborative Study Group. N Engl J Med* 2000;342:763-9.
- Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [see comments]. *N Engl J Med* 1997;337:141-7.

30. Srivastava MD. Immunomodulatory effects of etanercept (TNFR:Fc) and its use in a patient with Crohn's disease. *Res Commun Mol Pathol Pharmacol* 2001;109:125-41.
31. Taylor PC. Anti-tumor necrosis factor therapies. *Curr Opin Rheumatol* 2001;13:164-9.
32. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *N Engl J Med* 2006;355:704-12.
33. Sandborn WJ. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. *Rev Gastroenterol Disord* 2005;5:10-8.
34. Narula SK, Cutler D, Grint P. Immunomodulation of Crohn's disease by interleukin-10. *Agents Actions Suppl* 1998;49:57-65.
35. Rogler G, Andus T. Cytokines in inflammatory bowel disease. *World J Surg* 1998;22:382-9.
36. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor [alpha] (TNF[alpha]) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. *Ann Rheum Dis* 2005;64(suppl 4):iv2-14.
37. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-alpha therapies: the next generation. *Nat Rev Drug Discov* 2003;2:736-46.
38. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. *Nat Med* 2003;9:47-52.
39. Terkeltaub RA. IL-10: an "immunologic scalpel" for atherosclerosis? *Arterioscler Thromb Vasc Biol* 1999;19:2823-5.
40. Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. *Trends Cell Biol* 2001;11:372-7.
41. Ksontini R, MacKay SL, Moldawer LL. Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation. *Arch Surg* 1998;133:558-67.
42. Tanaka H, Sukhova G, Schwartz D, Libby P. Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but not interleukin-1 or basic fibroblast growth factor. *Arterioscler Thromb Vasc Biol* 1996;16:12-8.
43. Bluethmann H. Physiological, immunological, and pathological functions of tumor necrosis factor (TNF) revealed by TNF receptor-deficient mice. In: Durum SK, Muegge K, editors. *Cytokine knockouts*. Totowa, NJ: Humana Press; 1998. p. 69-87.
44. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. *Cell* 1988;53:45-53.
45. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhardt W, Carter HL, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. *Nature* 1997;385:733-6 [published erratum appears in *Nature* 1997;386:738].
46. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor- alpha from cells. *Nature* 1997;385:729-33.
47. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. *Cell* 2001;104:487-501.
48. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MAJ, Goeddel DV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. *Proc Natl Acad Sci U S A* 1991;88:9292-6.
49. Tartaglia LA, Rothe M, Hu YF, Goeddel DV. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. *Cell* 1993;73:213-6.
50. Tartaglia LA, Goeddel DV. Two TNF receptors. *Immunol Today* 1992;13:151-3.
51. Van Zee KO, Stackpole SA, Montegut WJ, Rogy MA, Calvano SE, Hsu KC, et al. A human tumor necrosis (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon. *J Exp Med* 1994;179:1185-91.
52. Welborn MB, Van Zee K, Edwards PD, Pruitt JH, Kaibara A, Vauthey JN, et al. A human tumor necrosis factor p75 receptor antagonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. *J Exp Med* 1996;184:165-71.
53. Wertheimer SJ, Myers CL, Wallace RW, Parks TP. Intercellular adhesion molecule-1 gene expression in human endothelial cells. Differential regulation by tumor necrosis factor-alpha and phorbol myristate acetate. *J Biol Chem* 1992;267:12030-5.
54. Couffignal T, Duplaa C, Labat L, Lamaziere JM, Moreau C, Printseva O, et al. Tumor necrosis factor-alpha stimulates ICAM-1 expression in human vascular smooth muscle cells. *Arterioscler Thromb* 1993;13:407-14.
55. Jovinge S, Hultgardh-Nilsson A, Regnstrom J, Nilsson J. Tumor necrosis factor-alpha activates smooth muscle cell migration in culture and is expressed in the balloon-injured rat aorta. *Arterioscler Thromb Vasc Biol* 1997;17:490-7.
56. Rus HG, Niculescu F, Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. *Atherosclerosis* 1991;89:247-54.
57. Clausell N, Molossi S, Sett S, Rabinovitch M. In vivo blockade of tumor necrosis factor-alpha in cholesterol-fed rabbits after cardiac transplant inhibits acute coronary artery neointimal formation. *Circulation* 1994;89:2768-79.
58. Fukumoto Y, Shimokawa H, Ito A, Kadokami T, Yonemitsu Y, Aikawa M, et al. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. *J Cardiovasc Pharmacol* 1997;29:222-31.
59. Rectenwald JE, Moldawer LL, Huber TS, Seeger JM, Ozaki CK. Direct evidence for cytokine involvement in neointimal hyperplasia. *Circulation* 2000;102:1697-702.
60. Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. *J Clin Invest* 1998;101:40-50.
61. Hoefler IE, van Royen N, Rectenwald JE, Bray EJ, Abouhamze Z, Moldawer LL, et al. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. *Circulation* 2002;105:1639-41.
62. Grundmann S, Hoefler I, Ulusans S, van Royen N, Schirmer SH, Ozaki CK, et al. Anti-tumor necrosis factor-[alpha] therapies attenuate adaptive arteriogenesis in the rabbit. *Am J Physiol Heart Circ Physiol* 2005;289:H1497-505.
63. Fernandez CM, Goldman DR, Jiang Z, Ozaki CK, Tran-Son-Tay R, Berceci SA. Impact of shear stress on early vein graft remodeling: a biomechanical analysis. *Ann Biomed Eng* 2004;32:1484-93.
64. Berceci SA, Jiang Z, Klingman NV, Schultz GS, Ozaki CK. Early differential MMP-2 and -9 dynamics during flow-induced arterial and vein graft adaptations. *J Surg Res* 2006;134:327-34.
65. Berceci SA, Jiang Z, Klingman NV, Pfahnl CL, Abouhamze ZS, Frase CD, et al. Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling. *J Vasc Surg* 2004;39:1084-90.
66. Jiang Z, Shukla A, Miller BL, Espino DR, Tao M, Berceci SA, et al. TNF- and the early vein graft. *J Vasc Surg*. 2007;45:169-76.
67. Jiang Z, Berceci SA, Pfahnl CL, Wu L, Goldman D, Tao M, et al. Wall shear modulation of cytokines in early vein grafts. *J Vasc Surg* 2004;40:345-50.
68. Scumpia PO, Moldawer LL. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. *Crit Care Med* 2005;33(12 suppl):S468-71.
69. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. *J Immunol* 1994;153:811-6.
70. Selzman CH, McIntyre RC Jr, Shames BD, Whitehill TA, Banerjee A, Harken AH. Interleukin-10 inhibits human vascular smooth muscle proliferation. *J Mol Cell Cardiol* 1998;30:889-96.
71. Zhang L, Peppel K, Brian L, Chien L, Freedman NJ. Vein graft neointimal hyperplasia is exacerbated by tumor necrosis factor receptor-1 signaling in graft-intrinsic cells. *Arterioscler Thromb Vasc Biol* 2004;24:2277-83.
72. Zimmerman MA, Reznikov LL, Raeburn CD, Selzman CH. Interleukin-10 attenuates the response to vascular injury. *J Surg Res* 2004;121:206-13.
73. Zimmerman MA, Reznikov LL, Sorensen AC, Selzman CH. Relative contribution of the TNF-alpha receptors to murine intimal hyperplasia. *Am J Physiol Regul Integr Comp Physiol* 2003;284:R1213-8.
74. Zimmerman MA, Selzman CH, Reznikov LL, Miller SA, Raeburn CD, Emmick J, et al. Lack of TNF-alpha attenuates intimal hyperplasia after

- mouse carotid artery injury. *Am J Physiol Regul Integr Comp Physiol* 2002;283:R505-12.
75. Sharony R, Pintucci G, Saunders PC, Grossi EA, Baumann FG, Gallo-way AC, et al. Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal-regulated kinases-1 and -2. *Am J Physiol Heart Circ Physiol* 2006;290:H1651-9.
 76. Edwards CK III, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, et al. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. *Adv Drug Deliv Rev* 2003;55:1315-36.
 77. Rosenberg JJ, Martin SW, Seely JE, Kinstler O, Gaines GC, Fukuzuka K, et al. Development of a novel, nonimmunogenic, soluble human TNF receptor type I (sTNFR-I) construct in the baboon. *J Appl Physiol* 2001;91:2213-23.
 78. Porat R, Paddock HN, Schwaitzberg SD, Connolly RJ, Wilkens T, Dasch JR, et al. Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit *Escherichia coli* sepsis. *Crit Care Med* 1995;23:1080-9.
 79. Fisher CJJ, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. *N Engl J Med* 1996;334:1697-702.
 80. Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. *JAMA* 1997;277:1531-8.
 81. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. *Crit Care Med* 1996;24:1431-40.
 82. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose- ranging study [see comments]. *Crit Care Med* 1996;24:733-42 [published erratum *Crit Care Med* 1996;24:1608].
 83. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;107:3133-40.
 84. Berceci SA, Jiang Z, Popp M, Tao M, Yu P, Ozaki CK. Transcriptional analyses of early shear stress induced vein graft adaptations. Presented at *Vascular* 2006. Jun 2, 2006.
 85. Miyake T, Aoki M, Shiraya S, Tanemoto K, Ogihara T, Kaneda Y, et al. Inhibitory effects of NFkappaB decoy oligodeoxynucleotides on neointimal hyperplasia in a rabbit vein graft model. *J Mol Cell Cardiol* 2006;41:431-40.
 86. Sartore S, Chiavegato A, Faggini E, Franch R, Puato M, Ausoni S, et al. Contribution of adventitial fibroblasts to neointima formation and vascular remodeling: from innocent bystander to active participant. *Circ Res* 2001;89:1111-21.
 87. Hinokiyama K, Valen G, Tokuno S, Vedin JB, Vaage J. Vein graft harvesting induces inflammation and impairs vessel reactivity. *Ann Thorac Surg* 2006;82:1458-64.
 88. Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, et al. Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. *Proc Natl Acad Sci U S A* 2006;103:15564-9.
 89. Biberthaler P, Bogner V, Baker HV, Lopez MC, Neth P, Kanz KG, et al. Genome-wide monocytic mRNA expression in polytrauma patients for identification of clinical outcome. *Shock* 2005;24:11-9.
 90. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. *Lancet* 1999;354:1493-8.
 91. Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. *Arterioscler Thromb Vasc Biol* 2004;24:470-6.

Submitted Jan 18, 2007; accepted Feb 13, 2007.